Hap Seng Consolidated Berhad First Quarter 2025 Earnings: EPS: RM0.041 (vs RM0.055 in 1Q 2024)
Net income: RM101.7m (down 26% from 1Q 2024).
Profit margin: 8.6% (down from 10% in 1Q 2024). The decrease in margin was driven by lower revenue.
EPS: RM0.041 (down from RM0.055 in 1Q 2024).
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hap Seng Consolidated Berhad's share price is broadly unchanged from a week ago.
You should always think about risks. Case in point, we've spotted 2 warning signs for Hap Seng Consolidated Berhad you should be aware of, and 1 of them is potentially serious.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Eindec First Half 2025 Earnings: S$0.003 loss per share (vs S$0.003 loss in 1H 2024)
Eindec (Catalist:42Z) First Half 2025 Results Key Financial Results Revenue: S$4.90m (down 2.0% from 1H 2024). Net loss: S$368.0k (loss widened by 1.1% from 1H 2024). S$0.003 loss per share (in line with 1H 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Eindec's share price is broadly unchanged from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 2 warning signs for Eindec you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
a day ago
- Yahoo
Pfizer (PFE) Reports Promising Phase 3 Results For Bladder Cancer Treatment Combination
Pfizer recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last quarter, Pfizer's stock saw an 11% rise, with these results potentially adding weight to this performance. The company also reached milestones in other research and development areas and maintained strong profitability, exemplified by a net income leap in its Q2 2025 earnings. Despite broader market trends pushing the S&P 500 and Nasdaq to record highs, Pfizer's product developments remain key contributors to its recent market position. We've spotted 2 warning signs for Pfizer you should be aware of. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource. The recent results from Pfizer's Phase 3 EV-303 trial offer promising insights for the company's oncology portfolio, potentially enhancing future revenue streams. Despite this positive development, Pfizer's shares experienced an 8.56% decline over the past year, reflecting challenges beyond short-term gains. In the broader context, Pfizer outperformed the US Pharmaceuticals industry, which saw a 16.1% decline over the same period, although it underperformed the overall US market, which returned 19.6%. The recent 11% rise in Pfizer's stock in the last quarter provides a contrast to the longer-term decline, suggesting a potential shift in investor sentiment influenced by recent successes in clinical trials. Analysts' consensus price target of approximately $28.86 suggests room for upside from the current share price of $24.65. However, projections must factor in the ongoing challenges of regulatory pressures and upcoming patent expirations, which may impact revenue and earnings forecasts. As the company continues to navigate these hurdles, the sustained advancement of its R&D initiatives remains a critical component in striving to achieve the forecasted revenue and earnings growth. Our comprehensive valuation report raises the possibility that Pfizer is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 days ago
- Yahoo
Marshalls First Half 2025 Earnings: EPS: UK£0.035 (vs UK£0.064 in 1H 2024)
Explore Marshalls's Fair Values from the Community and select yours Marshalls (LON:MSLH) First Half 2025 Results Key Financial Results Revenue: UK£319.5m (up 4.2% from 1H 2024). Net income: UK£8.90m (down 45% from 1H 2024). Profit margin: 2.8% (down from 5.2% in 1H 2024). The decrease in margin was driven by higher expenses. EPS: UK£0.035 (down from UK£0.064 in 1H 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Marshalls Earnings Insights Looking ahead, revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Basic Materials industry in the United Kingdom. Performance of the British Basic Materials industry. The company's share price is broadly unchanged from a week ago. Risk Analysis We should say that we've discovered 1 warning sign for Marshalls that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
